NuVasive (NuVasive) Total Current Assets : $728 Mil (As of Jun. 2023)

View and export this data going back to 2004. Start your Free Trial

What is NuVasive Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. NuVasive's total current assets for the quarter that ended in Jun. 2023 was $728 Mil.

NuVasive Total Current Assets Historical Data

The historical data trend for NuVasive's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NuVasive Total Current Assets Chart

NuVasive Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Current Assets

Get a 7-Day Free Trial

618.21

764.34

1,562.18

802.42

865.21

NuVasive Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Total Current Assets	Get a 7-Day Free Trial															823.31	843.23	865.21	806.36	728.25

NuVasive Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

NuVasive's Total Current Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	248.663	+	249.373	+	338.601	+	28.575
	=	865

NuVasive's Total Current Assets for the quarter that ended in Jun. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	80.718	+	267.105	+	350.805	+	29.626
	=	728

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

NuVasive (NAS:NUVA) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

NuVasive's Liquidation Value for the quarter that ended in Jun. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	80.718	-	1197.007	+	0.75 * 267.105	+	0.5 * 350.805
=	-741

NuVasive Total Current Assets Related Terms

Thank you for viewing the detailed overview of NuVasive's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

NuVasive (NuVasive) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NuVasive Inc (NAS:NUVA) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

12101 Airport Way, Broomfield, CO, USA, 92121

Website

https://www.nuvasive.com

NuVasive Inc is a medical technology company focused on developing, manufacturing, selling and providing procedural solutions for spine surgery, with a guiding purpose to transform surgery, advance care and change lives. The company has a portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. It also develop and sell magnetically adjustable implant systems for spine and specialized orthopedic procedures.

Executives

Michael Farrington	officer: SVP, People and Culture	7475 LUSK BLVD., SAN DIEGO CA 92121
Marc W. Rosenbaum	officer: Chief Accounting Officer	7475 LUSK BLVD., SAN DIEGO CA 92121
James Christopher Barry	director, officer: Chief Executive Officer	7475 LUSK BLVD, SAN DIEGO CA 92121
Andrew C. Morton	officer: SVP, CHRO	10910 DOMAIN DRIVE, SUITE 300, AUSTIN TX 78758
Amy Belt Raimundo	director	ONE KAISER PLAZA, 22ND FLOOR, OAKLAND CA 94612
Lucas Vitale	officer: Chief Human Resources Officer	7475 LUSK BLVD, SAN DIEGO CA 92121
Massimo Calafiore	officer: EVP, Global Business Units	7475 LUSK BLVD., SAN DIEGO CA 92121
Siddhartha Kadia	director	7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Vickie L Capps	director	2985 SCOTT STREET, VISTA CA 92083
Brent J. Boucher	officer: EVP, Global Commercial	14 PLAZA DRIVE, LATHAM NY 12110
Matthew Link	officer: Exec. VP U.S. Sales	7475 LUSK BLVD, SAN DIEGO CA 92121
Matthew K Harbaugh	officer: EVP and CFO	675 MCDONNELL BLVD., HAZELWOOD MO 63042
Dale A. Wolf	officer: SVP, Global Operations	7475 LUSK BLVD., SAN DIEGO CA 92121
Gregory T Lucier	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Mcclintock	officer: President, U.S. Commercial	7475 LUSK BLVD, SAN DIEGO CA 92121